Browsing Tag
NASDAQ: TLX
1 post
Telix Pharmaceuticals (ASX: TLX) jumps 16% after CMS greenlight and Illuccix’s European rollout
Telix Pharmaceuticals raises FY25 revenue guidance after securing CMS reimbursement for Gozellix and accelerating Illuccix's launch in Europe. Learn what’s next.